Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (RXRX), a clinical stage TechBio company focused on drug discovery, has announced it will release its Q4 and full-year 2024 financial results on February 28, 2025, before market open. The company will host a live earnings call at 8:30 AM ET/6:30 AM MT/1:30 PM GMT on the same day.
The earnings call will be broadcast live through Recursion's social media channels including X (formerly Twitter), LinkedIn, and YouTube. Stakeholders, including investors and analysts, will have the opportunity to submit questions through a dedicated link.
Altitude Lab, a biotech accelerator founded by Recursion (NASDAQ: RXRX), has launched a pre-seed venture fund to support early-stage biotechnology startups affected by federal funding policy changes. The fund will provide $100,000–$250,000 in pre-seed investment capital, 12 months of lab space, and admission to Altitude Lab's accelerator program.
The initiative aims to bridge the gap created by recent policy shifts that have impacted approximately 1,500 health-related startups dependent on Small Business Innovation Research (SBIR) grants. The fund will be led by Recursion CEO Chris Gibson, alongside entrepreneur David Bearss and Altitude's executive director Chandana Haque.
Altitude Lab's startups have raised $154M from 2020 to 2024, representing over 50% of life science-focused early-stage capital in Utah. Eligible startups must have received an Impact Score of 20 or less in a recent SBIR submission.
Altitude Lab, founded by Recursion (NASDAQ: RXRX), announced that its incubating startups have raised $154 million in early-stage funding since 2020. The lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, CEO of Elnora AI, providing $150,000 in funding and support.
Key achievements include:
- 19 current startups and 12 alumni
- 70% of startups led by underrepresented founders
- 90% of participating startups have raised capital
Notable portfolio milestones include Peel Therapeutics completing Phase 1 trial and initiating Series A, Rebel Medicine receiving IND approval and starting Series A, Sethera appointing Moderna co-founder as advisory board chair, and Teiko launching a 25-marker spectral flow cytometry assay.
Recursion (RXRX) has reported positive 12-month data from its Phase 2 SYCAMORE trial of REC-994 for Cerebral Cavernous Malformations (CCM). The study met its primary endpoint of safety and tolerability, with no treatment-related discontinuations or Grade 3 adverse events.
Key findings for the 400mg dose include: 50% of patients showed reduction in total lesion volume versus 28% in placebo, with an absolute mean decrease of 457 mm³ compared to a 53 mm³ increase in placebo. Patients demonstrated trends toward improvement in modified Rankin scale (mRS) scores, particularly in those with brainstem lesions.
The most common adverse events included Covid-19, dizziness, headache, back pain, and constipation. The company plans to determine next steps through regulatory discussions and ongoing long-term extension study results.
Recursion (NASDAQ: RXRX) has received regulatory clearances for two key oncology drugs to advance to clinical trials. The UK MHRA cleared a Phase 1 trial for REC-3565, a MALT1 inhibitor targeting B-cell malignancies, with a potential addressable market of 41,000 relapsed/refractory patients with chronic lymphocytic leukemia and B-cell lymphomas in US+EU5 annually.
The FDA cleared an IND application for REC-4539, a reversible and CNS-penetrant LSD1 inhibitor for small-cell lung cancer, targeting approximately 45,000 extensive stage SCLC patients annually in US+EU5. REC-3565 is designed to reduce hyperbilirubinemia risk, while REC-4539 is the first reversible LSD1 inhibitor designed to penetrate the brain.
Recursion (NASDAQ: RXRX), a clinical stage TechBio company, has announced that its co-founder and CEO Chris Gibson, PhD, will deliver a presentation at the 43rd Annual JP Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, at 7:30am PT (10:30am ET) in the Elizabethan Room A/B at the Westin St. Francis.
Dr. Gibson will provide updates on three key areas: Recursion's clinical pipeline, partnerships, and platform developments following the company's recent merger with Exscientia. The presentation will be accessible on Recursion's investor relations website for a minimum of 30 days after the event.
Iambic Therapeutics has appointed Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer. Dr. Secora, formerly CFO at Recursion (NASDAQ: RXRX), brings extensive experience in technology-driven drug development, combining scientific, capital markets, and business expertise.
At Recursion, he led finance, communications, and investor relations, orchestrating collaborations with major companies like Bayer and Roche-Genentech, and raising over $1.3 billion through private and public funding rounds.
Iambic's pipeline includes IAM1363, a HER2 inhibitor in Phase 1 with data expected in 2025, along with other programs including a dual CDK2/4 inhibitor and an allosteric KIF18A inhibitor. The company's platform integrates chemical synthesis, mass spectrometry, and AI technology, demonstrating ability to advance from program initiation to Phase 1 trials in approximately 2 years.
Recursion Pharmaceuticals (NASDAQ: RXRX) announced the approval of inducement restricted stock unit (RSU) awards by its Board's Compensation Committee on December 19, 2024. The grants cover 7,952,836 shares of class A common stock, distributed among 230 new employees under the company's 2024 Inducement Equity Incentive Plan. These awards were granted in connection with Recursion's acquisition of Exscientia plc. The RSUs will vest quarterly at a rate of 1/16th of shares on February 15, May 15, August 15, and November 15, starting February 15, 2025, contingent on continued employment.
Recursion (RXRX) announced interim Phase 1 clinical data for REC-617, their CDK7 inhibitor, showing promising results in advanced solid tumors. The study included 18 response-evaluable patients with doses ranging from 2mg to 20mg once daily and 1mg twice daily.
Key highlights include a confirmed partial response in a platinum-resistant ovarian cancer patient, ongoing after 6+ months of treatment, and stable disease in four additional patients for up to 6 months. The drug demonstrated favorable tolerability with predominantly Grade 1-2 adverse events and no treatment discontinuations.
REC-617 showed rapid absorption, dose-linear pharmacokinetics, and robust biomarker modulation. The company plans to continue monotherapy dose escalation and initiate combination studies in first half of 2025.
Recursion (NASDAQ: RXRX) has initiated dosing in its Phase 1/2 DAHLIA clinical trial of REC-1245, a novel RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma. The drug, developed using AI-powered biology mapping, moved from target identification to IND studies in under 18 months. REC-1245 works by inducing splicing defects that downregulate DNA Damage Response networks and cell cycle checkpoints, potentially addressing over 100,000 patients in the US and EU5. The DAHLIA trial aims to evaluate safety, tolerability, and preliminary activity, while determining maximum tolerated dose for both single-agent use and combinations with other treatments.